ABSTRACT
Purpose To identify which acute and 6-month domain-specific cognitive impairments impact mood functioning, participation, and stroke-related quality of life 6 months after stroke.
Materials and Methods A prospective cohort of 430 stroke survivors completed the Oxford Cognitive Screen (OCS) acutely and 6 months post-stroke. Participants completed the Stroke Impact Scale (SIS) and Hospital Depression and Anxiety Scale (HADS) at 6 months. Multivariable regression analyses assessed whether severity of, and domain-specific, cognitive impairment acutely and at 6 months was associated with composite 6-month SIS scores, each SIS subscale, and HADS scores.
Results Increased severity of cognitive impairment acutely and at 6 months was associated with lower 6-month SIS composite scores independent of age, sex, education years, and stroke severity (both p<0.001). Domain-specific impairments in memory (p<0.001) and attention (p=0.002) acutely, and language (p<0.001), memory (p=0.001) and number processing (p=0.006) at 6 months showed the strongest associations with worse SIS composite scores. Severity of acute and 6-month cognitive impairment was associated with poorer functioning in each SIS subscale, as well as greater levels of depression (acute p=0.021, 6-months p<0.001), but not anxiety (p=0.174, p=0.129).
Conclusions Both acute and 6-month domain-specific cognitive impairments, particularly in memory, were found to negatively impact overall functional and mood outcomes 6 months post-stroke.
Competing Interest Statement
ND is a developer of the Oxford Cognitive Screen but does not receive renumeration for its use. STP has received honoraria from Trondheim, Sydney and LaTrobe universities and royalties from Oxford University Press and Cambridge University Press.
Funding Statement
This study was funded by the Stroke Association (SA PPA 18/100032). ND is supported by an NIHR Advanced Fellowship (NIHR302224). STP is supported by the NIHR Oxford BRC. This study was supported by the NIHR Clinical Research Network. The views expressed are those of the authors and not necessarily those of the NHS, NIHR or Department of Health. We thank all participants and members of the Oxford Translational Neuropsychology Group for contributions to recruitment/testing
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
National Research Ethics Committee (UK) gave approval for this work (references 14/LO/0648 and 18/SC/0550)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The participants of this study did not give written consent for their individual data to be shared publicly, so due to the sensitive nature of the research supporting data is not available.
